Saturday 17 October 2026
Export RNAC’s income statement to Excel — free account
Cartesian Therapeutics, Inc.
RNAC Healthcare Biotechnology
Cartesian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 92.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.9%, EPS fell 7.84% and free cash flow fell 6.15%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.27
0.31
−4.71%
Follow RNAC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 2 | 2 | 2 |
+8 more TTM periods Free account |
| 236.88% | 178.66% | 195.88% | 264.44% | ||
| (42.77%) | (43.52%) | (35.63%) | (11.21%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(104.80%) | (128.92%) | (102.99%) | (31.81%) | |
Average Days of Receivables |
0.00 | 53.67 | 145.50 | 241.55 | |
Free Cash Flow per Share |
(2.67) | (2.88) | (3.06) | (2.64) | |
Free Cash Flow |
(78.61) | (77.37) | (79.39) | (68.55) | |
Capital Expenditures |
(2.08) | (4.41) | (5.45) | (5.32) | |
| Other line items | |||||
Cash ROIC |
(104.49%) | 262.49% | 7,211.17% | (63.74%) | |
Accounts Receivable Turnover |
0.00 | 1.75 | 2.82 | 0.33 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 3,539.32% | 2,074.87% | 5,009.26% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 1,705.18% | 1,125.06% | 2,782.58% | |
Share Based Compensation of Revenue |
0.00% | 587.94% | 376.15% | 938.77% | |
Interest Coverage |
(54.00) | — | — | — | |
Operating CF/Net income |
0.51 | 0.48 | 0.57 | 1.36 | |
Depreciation/Fixed assets |
0.23 | 0.21 | 0.24 | 0.23 | |
Capex/Depreciation |
(0.80) | (1.82) | (1.84) | (1.87) | |
Revenue per Share |
0.00 | 0.07 | 0.11 | 0.04 | |
Operating CF per Share |
(2.60) | (2.72) | (2.85) | (2.43) | |
Capex per Share |
(0.07) | (0.16) | (0.21) | (0.20) | |
Capex to Sales |
0.00 | 2.48 | 1.95 | 4.87 |
Columns are period end dates